IL‑10 is a potent anti‑inflammatory cytokine secreted mainly by T cells, B cells, macrophages, and dendritic cells. It modulates innate and adaptive immunity by suppressing pro‑inflammatory mediators and promoting regulatory cell functions. IL‑10 plays a critical role in limiting tissue damage during infections and in preventing autoimmune disease.

## 2. Location & Context
- Extracellular cytokine; secreted into the circulation and local tissues.  
- Expressed at high levels by activated `Treg`, `Th2`, and `Th17` cells; also by `M2` macrophages.  
- Concentrations reach up to 10–100 ng mL⁻¹ during acute inflammation.

## 3. Classification & Structure
- Belongs to the `IL‑10` cytokine family; shares ~40 % sequence identity with `IL‑19`, `IL‑20`, and `IL‑24`.  
- 159‑aa mature protein; two alpha‑helical bundles, a C‑terminal loop, and a disulfide bond between Cys 56 and Cys 122.  
- Contains the signature IL‑10 cytokine domain (pfam PF00581).

## 4. Physiological / Biological Function
- Inhibits `TNF-α`, `IL‑1β`, and `IL‑6` production by macrophages.  
- Suppresses `MHC‑II` expression on antigen‑presenting cells.  
- Promotes `B cell` differentiation into plasma cells and IgG1 production.

## 5. Molecular/Structural Derivatives
- Alternative splicing yields a short variant lacking residues 27–38, which has reduced receptor affinity.  
- Post‑translationally modified by N‑glycosylation at Asn 87; essential for stability.

## 6. Metabolism & Biotransformation
- Synthesized in the cytosol, processed through the ER–Golgi pathway.  
- Degraded extracellularly by proteases such as matrix metalloproteinase‑9.  
- No known metabolic conversion to smaller active peptides.

## 7. Receptor Binding & Signaling
- Binds the heterodimeric receptor complex `IL‑10Rα` + `IL‑10Rβ`.  
- Triggering leads to `JAK1`/`Tyk2` phosphorylation → `STAT3` activation → transcription of anti‑inflammatory genes.  
- Can also activate `PI3K–AKT` and `MAPK` pathways in certain cell types.

## 8. Tissue‑Specific Actions
- In the gut, IL‑10 limits colitis by reducing dendritic cell activation.  
- In the central nervous system, it dampens microglial activation during neuroinflammation.  
- In the liver, IL‑10 promotes hepatocyte survival after injury.

## 9. Interaction with Other Biomolecules
- Synergizes with `TGF‑β` to expand regulatory T cells.  
- Antagonizes `IL‑12` and `IL‑23` signaling in Th1/Th17 cells.  
- Interacts with `SOCS3` to terminate STAT signaling.

## 10. Genetic Polymorphisms & Variants
- SNP `-1082 G>A` (IL‑10 promoter) influences transcriptional activity and is associated with susceptibility to inflammatory bowel disease.  
- Polymorphisms at positions `−819 C>T` and `−592 C>A` modulate serum IL‑10 levels.  
- Loss‑of‑function mutations in `IL10RA` cause severe early‑onset inflammatory bowel disease.

## 11. Dietary & Environmental Influences
- Short‑chain fatty acids (butyrate) enhance IL‑10 production by colonic macrophages.  
- Vitamin D upregulates IL‑10 expression in monocytes via the vitamin D receptor.  
- Exposure to endotoxins (LPS) transiently boosts IL‑10 secretion as a feedback mechanism.

## 12. Pathophysiological Associations
- Elevated IL‑10 is a biomarker for active tuberculosis and sepsis; can indicate immune suppression.  
- Reduced IL‑10 levels are implicated in rheumatoid arthritis, asthma, and multiple sclerosis.  
- Dysregulated IL‑10 signaling contributes to chronic inflammatory disorders and certain cancers by creating an immunosuppressive microenvironment.

## 13. Therapeutic Relevance
- Recombinant human IL‑10 (`tacrolimus‑associated immunomodulatory therapy`) is in clinical trials for Crohn’s disease and graft‑vs‑host disease.  
- Neutralizing antibodies against IL‑10 are explored to potentiate anti‑tumor immunity.  
- Small molecules that enhance IL‑10 production (e.g., histone deacetylase inhibitors) show promise in autoimmune disease models.